Revvity stock
Price history
+54.46% over the period1 year: from $94.02 (November 20, 2025) to $145.22 (November 20, 2026), +54.46%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | $145.22 |
| October 30, 2026 | $157.00 |
| September 30, 2026 | $152.89 |
| August 31, 2026 | $128.67 |
| July 31, 2026 | $112.52 |
| June 30, 2026 | $111.26 |
| May 29, 2026 | $104.55 |
| April 30, 2026 | $86.62 |
| March 31, 2026 | $87.61 |
| February 27, 2026 | $98.31 |
| January 30, 2026 | $108.80 |
| December 31, 2025 | $96.75 |
| November 28, 2025 | $104.41 |
| November 20, 2025 | $94.02 |
At a glance
The company
Provides health sciences solutions, instruments, reagents, software and services for diagnostics, genomics and drug discovery
Latest results
Quarter to September 30, 2026 · EPS $1.37 (estimate $1.30)
Next event
Dividend
TickerLandia's take on Revvity
- Pricier than usual relative to earnings: P/E on the latest fiscal year 70 vs a median of 29 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 65 vs 34 (+90%) in a group of 9.
- Strong point: Market momentum (96/100 in its group). Weak point: Growth (34/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−15.44% from the 52-week high
Analysts · 18 analysts
Average target$171.40+18.03% vs. price
Buy 6 · Hold 11 · Sell 1 · Buy
TickerLandia Fingerprint: Revvity
Compared with similar companies: very strong momentum.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 888 North American stocks.
Priceaverage56
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 24.4 70 P/E (trailing 12 months) 64.5 85 EV/EBITDA 20.4 54 Price/sales 5.51 54 Price/book 2.23 17 Profitabilitylow37
How much it earns on revenue and capital.
Metric Value Position in group Net margin 8.6% 43 ROE 3.5% 17 Gross margin 55.9% 57 Operating margin 16.7% 54 ROA 2.6% 13 Earnings stabilitylow37
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 9.4% 13 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 61 Growthlow34
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) −4.82% 6 Earnings growth (year over year) +37.80% 68 Revenue growth (year over year) +4.30% 28 Financial strengthaverage52
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 2.95 18 Interest coverage 4.73 29 Debt/equitycounts in reverse: lower means more financial strength 0.38 72 Current ratio 2.65 87 Dividendlow37
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 37 years 97 Payout ratio 12.4% 9 Dividend yield 0.2% 3 Market momentumvery strong96
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +29.36% 96 Relative strength (6 months) +64.77% 98 1-year return +54.46% 94 Distance from 200-day average +26.10% 98 Riskhigh63
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 30.1% 51 Volatility (60 days) 43.7% 66 Beta (1 year) 1.21 71
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Revvity is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Revvity's P/E today is 70.2, above the median of its last 10 fiscal years (29.4; between 19.7 and 50.9 from 2016 to 2025). Revvity's P/E (trailing 12 months): 64.5, +90% against the median of a group of 9 similar companies (33.9).
Compared with 9 similar companies
| Metric | Revvity | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 64.5 | Middle | |
| Forward P/E | 24.4 | Middle | |
| Operating margin | 16.7% | Middle | |
| ROE | 3.5% | Low | |
| Debt/equity | 0.38 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Revvity. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$728.9M
Latest quarter · Q3 2026
Net income
$62.3M
Latest quarter · Q3 2026
Quarterly net margin
8.5%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $16.21B
- P/E
- 64.5
- EPS
- $2.25
- Volume
- 1.66M
- Daily trading
- €259.56M
- Dividend yield
- 0.19%
How Revvity is changing
All resultsRevenue fell 5.5% a year on average over the last 5 years
Operating margin fell from 22.4% to 12.5%
Free cash flow equal to 88% of net income
Returns
Revvity returns with dividends
$1,000 invested in Revvity 5 years ago, on November 22, 2021, would be worth $809 today with dividends reinvested: −19.13% in total, −4.16% per year. On price alone it would be $799 (−20.10%).
| Period | Revvity | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −6.92% | −10.40% | $931 |
| 6 months | +53.19% | −7.03% | $1,532 |
| Year to date | +50.10% | +0.95% | $1,501 |
| 1 year | +54.83% | +5.68% | $1,548 |
| 3 years | +66.10% | +51.96% | $1,661 |
| 5 years | −19.13% | +47.57% | $809 |
| 10 years | +195.22% | +214.37% | $2,952 |
Over the last 6 months it has done better than 94% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Revvity: technical analysis
Revvity shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 27.8% below its highest close since January 2, 1990 ($201.06, December 31, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 41
- Between 30 and 70
- vs 200-session average
- +26.10%
Active signals
Close below the low of the previous 20 sessions.
Support and resistance
Price areas where Revvity has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$148.04+1.94%2 touches, last on November 6, 2026
- Last price$145.22
- Support$116.30−19.91%5 touches, last on August 18, 2026
- Support$107.88−25.72%2 touches, last on August 4, 2026
- Support$104.14−28.29%7 touches, last on July 21, 2026
Volatility and risk
Over the last year it has moved more than the S&P 500.
- Beta (1 year) vs S&P 500
- 1.21
- Volatility (60 sessions, annualised)
- 43.7%
- Largest fall in the last year
- −30.14%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Revvity: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Revvity has been December: +3.70% on average, positive in 25 years out of 36. The weakest has been March: −1.25% on average, positive in 17 years out of 37. November, the current month, has been positive in 24 years out of 36 (+1.68% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +2.86% | +2.12% | 20 of 36 |
| February | +0.38% | +2.02% | 22 of 37 |
| March | −1.25% | −0.57% | 17 of 37 |
| April | −0.55% | −0.54% | 16 of 37 |
| May | +3.61% | +3.41% | 26 of 37 |
| June | +0.17% | −1.48% | 16 of 37 |
| July | +0.36% | +1.13% | 20 of 37 |
| August | +0.72% | +0.81% | 19 of 37 |
| September | −0.05% | −1.49% | 16 of 37 |
| October | +1.97% | +2.55% | 23 of 37 |
| November | +1.68% | +2.10% | 24 of 36 |
| December | +3.70% | +3.05% | 25 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Revvity and its competitors
Known for its EUROIMMUN, IDS-iSYS and DELFIA diagnostic assays, BioLegend antibodies and Cellometer cell counters, Revvity offers instruments, reagents, software and services for health sciences. Its diagnostics range covers early detection screening, including pregnancy and early childhood tests for genetic disorders such as Down syndrome and hypothyroidism, as well as infectious disease testing. Research tools support genomic workflows, oncology, immunodiagnostics and drug discovery, with products such as Dharmacon reagents and AlphaLISA assays.
- Headquarters
- Waltham, United States
- Employees
- 11,000
- Founded
- 1937
- Chief executive
- Prahlad Singh
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| RevvityRVTY | $16.21B | 16.7% | 64.5 | +53.19% |
| Medpace HoldingsMEDP | $17.08B | 21.4% | 33.9 | +44.72% |
| Charles River Laboratories InternationalCRL | $15.06B | 14.3% | 341.7 | +101.45% |
| ICON PublicICLR | $13.99B | 2.7% | 74.7 | +62.23% |
| Guardant HealthGH | $19.73B | -39.4% | — | +26.84% |
| Quest DiagnosticsDGX | $28.42B | 14.9% | 25.7 | +33.31% |
Same industry or related industries, similar size. Compare Revvity with its competitors · Full profile
